- In February 2024, researchers at Cornell University unveiled an engineered bacterium known as Vibrio natriegens, which demonstrates enhanced competency for plasmid DNA. This innovative strain can be engineered in just a few hours, making it a valuable tool for synthetic biology research. The rapid engineering capability of Vibrio natriegens positions it as a promising candidate for various applications in genetic manipulation and biotechnological advancements
- In February 2024, Bio-Rad Laboratories, Inc. introduced two innovative products: the Vericheck ddPCR Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit. These kits are designed to enhance cell and gene therapy production by providing reliable tools for quantifying replication-competent viral vectors. The launch of these products reflects Bio-Rad's commitment to advancing technologies that support the growing demands of gene therapy and cell-based applications in the biotechnology sector
- In December 2023, CCM Biosciences (CCM Bio) unveiled the 5Prime Sciences Business Unit, dedicated to advancing the development and application of proprietary technologies in DNA biotechnology. This new unit emphasizes molecular cloning and aims to enhance the efficiency and effectiveness of genetic manipulation techniques. The establishment of the 5Prime Sciences Business Unit highlights CCM Bio's commitment to innovation and leadership in the rapidly evolving field of DNA biotechnology
- In December 2021, Thermo Fisher Scientific Inc. completed the acquisition of PeproTech, Inc., a company renowned for its development and production of recombinant proteins, including essential cytokines and growth factors. This strategic acquisition significantly broadened Thermo Fisher’s biosciences product portfolio, enhancing its capabilities in the biotechnology sector. By integrating PeproTech’s expertise and innovative products, Thermo Fisher aims to better serve the growing demands of researchers and clinicians in areas such as immunology and cell biology
- In January 2020, SGI-DNA launched its Vmax™ X2 Competent Cells, engineered to significantly enhance protein production efficiency. These advanced competent cells can generate two to four times more soluble protein in just half the time compared to traditional E. coli methods. This innovation represents a substantial improvement in the speed and yield of protein expression, making it a valuable tool for researchers in the biotechnology and pharmaceutical fields
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Chemically Competent Cell and Electrocompetent Cells), Application (Protein Expression, Cloning, Biotechnology, and Other Applications), End User (Pharmaceutical and Biotechnology Companies, Academic Research Institutes, and Contract Research Organizations (CROs)) – Industry Trends and Forecast to 2031
.
The Global Competent Cells Market size was valued at USD 2.04 USD Billion in 2023.
The Global Competent Cells Market is projected to grow at a CAGR of 10.11% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
